

R. Castillejo García<sup>1</sup>, Luz de Luna Rueda Bermudez<sup>1</sup>, Gabriel Ramírez Soto<sup>1</sup>, Noemí Rebollo Díaz<sup>1</sup>, Álvaro López Díaz<sup>2</sup>

<sup>1</sup>Pharmacy, <sup>2</sup>Psychiatry, Hospital Universitario Virgen Macarena, Sevilla, Spain.

## BACKGROUND AND IMPORTANCE

The effectiveness of second generation antipsychotics (SGA) has been shown to be equivalent to the first-generation antipsychotics (FGA), with different side effect profiles.

## AIM AND OBJECTIVES

The aim of this study was to **determine the patterns of antipsychotics prescription and related costs at a university hospital.**

## MATERIAL AND METHODS





- ✓ One year **retrospective observational study** at a Spanish university general hospital.
- ✓ Identification of **outpatients under treatment with antipsychotics** during 2021.
- ✓ **FGA and SGA data consumption** was obtained from **Microstrategy®** database.

- ✓ Percentage of patients with SGA, FGA and long-acting antipsychotics (LAI).
- ✓ Costs per patient.



## RESULTS

16.967 patients under treatment with antipsychotics (2021)



9.01% FGA	90.9% SGA
Oral haloperidol (44.4%)	Oral quetiapine (37.3%)
Oral clotiapine (26.6%)	Oral olanzapine (20.2%)
Oral levomepromazine(17.9%)	Oral aripipazole (15.7%)
Oral chlorpromazine (3,82%)	Oral risperidone (11.4%)

The use of **LAI** was **6.66% (3.43% and 6.98% among FGA and SGA, respectively)**. The **95.31% total LAI prescriptions were SGA.**

- The use of **LAI at hospital** was found to be **lower** than in other **European countries (15%)**
- The proportion of **second generation LAI** was **higher** than the **European average (34%)**.
- The **mean cost per patient** was higher for **SGA** than for **FGA (353.5€ vs 27.0€)**.
- In comparison to conventional injectable antipsychotics, **costs per patient** were higher for **LAI: 155.1€ vs 15.8€ for FGA and 2887.5€ vs 72€ for SGA, respectively.**



## CONCLUSION AND RELEVANCE

- In comparison with other European countries, a **predominance of the use of second generation LAI** has been detected. However, the use of LAI is lower.
- **Cost-effectiveness studies** regarding the use of **SGA versus FGA** and **conventional versus LAI antipsychotics** are needed in order to **optimize the benefits to the patient** and **minimize the economic burden for the health system.**